Candel Therapeutics, Inc. is a BLA-ready clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic antitumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patientโs specific tumor and induce an individualized, systemic immune response against the tumor.
์ข
๋ชฉ ์ฝ๋ CADL
ํ์ฌ ์ด๋ฆCandel Therapeutics Inc
์์ฅ์ผJul 27, 2021
CEOTak (Paul Peter)
์ง์ ์38
์ ํOrdinary Share
ํ๊ณ ์ฐ๋ ์ข
๋ฃJul 27
์ฃผ์117 Kendrick Street,
๋์NEEDHAM
์ฆ๊ถ ๊ฑฐ๋์NASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐUnited States of America
์ฐํธ ๋ฒํธ02494
์ ํ16179165445
์น์ฌ์ดํธhttps://www.candeltx.com/
์ข
๋ชฉ ์ฝ๋ CADL
์์ฅ์ผJul 27, 2021
CEOTak (Paul Peter)
์ง๋ 5๋
๋์ ์ด
0.00
USD์ ๋ฐฐ๋น๊ธ์ด ๋ถ๋ฐฐ๋์์ต๋๋ค.

๋ฐ์ดํฐ ์์